Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03063749 · ClinicalTrials.gov registry record
RESOLUTE ONYX Post-Approval Study
A clinical trial, sponsored by Medtronic Vascular.
- Completed
- Registry status
- 416
- Enrollment target
NCT03063749: Completed study, sponsored by Medtronic Vascular.
NCT03063749 is a clinical trial that has completed, run by Medtronic Vascular. The registered enrollment target is 416 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03063749 has completed, sponsored by Medtronic Vascular.
- COMPLETED
- Registry status
- 416 participants
- Enrollment target
Study Summary
To observe the continued performance of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in a real-world more-comer population.
Primary Outcome
Target Lesion Failure (TLF), defined as cardiac death, target vessel myocardial infarction (Q wave and non-Q wave), or clinically driven target lesion revascularization (TLR) by percutaneous or surgical methods
Interventions
- DEVICE Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 416 participants |
| Start Date | 2017-03-30 |
| Est. Completion | 2022-08-18 |
What the finished NCT03063749 record still lists
NCT03063749 is an observational study that tracks outcomes without assigning an intervention. The registered 416 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System is the first listed.
NCT03063749 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03063749 about?
NCT03063749 is a clinical study titled "RESOLUTE ONYX Post-Approval Study". To observe the continued performance of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in a real-world more-comer population.
What is the current status of trial NCT03063749?
This trial is currently completed. The enrollment target is 416 participants. The study started on 2017-03-30. Estimated completion is 2022-08-18.
What interventions are being tested in trial NCT03063749?
The interventions under investigation include: Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System (DEVICE).
Who is sponsoring clinical trial NCT03063749?
This trial is sponsored by Medtronic Vascular, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03527537 · 416 participants · Phase 4
Gestational Diabetes and Pharmacotherapy (GAP)
- NCT05007782 · 416 participants · Phase 1
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
- NCT05520099 · 416 participants
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
- NCT06075745 · 416 participants · Phase 2
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI